Optimizing dosage regimens in critically ill patients with glomerular hyperfiltration
DOI:
https://doi.org/10.30445/rear.v14i2.980Keywords:
augmented renal clearance, critically ill, glomerular hyperfiltrationAbstract
Glomerular hyperfiltration is a phenomenon defined by creatinine clearance greater than 130 ml / min / 1.72 m2. A very wide range of incidence has been described in critically ill patients. The use of conventional doses of renal elimination drugs in patients with glomerular hyperfiltration can cause therapy failure, with worse patient outcomes and increased costs. The purpose of this review is to provide an updated summary of the current evidence on glomerular hyperfiltration in critically ill patients. For the preparation of this document, a non-systematic review of articles indexed in MEDLINE (PubMed) of the last twenty years has been carried out, updated in December 2019, using the keywords “augmented renal clearance”, “critically ill”, "Glomerular hyperfiltration", "hyperfiltration" and "creatinine clearance".
References
National Kidney Foundation Kidney Disease Quality Outcome Initiative (K/DOQI) Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 2002 39:S46 75, (suppl 1).
Udy, A.A.; Putt, M.T.; Shanmugathasan, S.; Roberts, J.A.; Lipman, J. Augmented renal clearance in the intensive care unit: An illustrative case series. Int. J. Antimicrob. Agents 2010, 35, 606–608.
Veerle Grootaert, Ludo Willems, Yves Debaveye, Geert Meyfroidt, and Isabel Spriet. Augmented Renal Clearance in the Critically Ill: How to Assess Kidney Function. Ann Pharmacother 2012;46(7-8):952-9.
Dahlquist, G., Stattin, E. L. & Rudberg, S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol. Dial. Transplant. 2001 16, 1382–1386.
Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005;16: 459-66.
Ichai, C.; Passeron, C.; Carles, M.; Bouregba, M.; Grimaud, D. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: A single-blind, prospective, controlled study. Crit. Care Med. 2000, 28, 1329–1335.
Minville, V.; Asehnoune, K.; Ruiz, S.; Breden, A.; Georges, B.; Seguin, T.; Tack, I.; Jaafar, A.; Saivin, S.; Fourcade, O.; et al. Increased creatinine clearance in polytrauma patients with normal serum creatinine: A retrospective observational study. Crit. Care (Lond. Engl.) 2011, 15, R49.
Udy, A.A.; Roberts, J.A.; Shorr, A.F.; Boots, R.J.; Lipman, J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: Identifying at-risk patients. Crit. Care (Lond. Engl.) 2013, 17, R35
Akers, K.S.; Niece, K.L.; Chung, K.K.; Cannon, J.W.; Cota, J.M.; Murray, C.K. Modified augmented renal clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. J. Trauma Acute Care Surg. 2014, 77, 163.
Barletta, J.F.; Mangram, A.J.; Byrne, M.; Sucher, J.F.; Hollingworth, A.K.; AliOsman, F.R.; Shirah, G.R.; Haley, M.; Dzandu, J.K. Identifying augmented renal clearance in trauma patients: Validation of the augmented renal clearance in trauma intensive care (arctic) scoring system. J. Trauma Acute Care Surg. 2017, 82, 665–671.
Huttner, A.; Von Dach, E.; Renzoni, A.; Huttner, B.D.; Affaticati, M.; Pagani, L.; Daali, Y.; Pugin, J.; Karmime, A.; Fathi, M.; et al. Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study. Int. Antimicrob. Agents 2015, 45, 385–392.
Akers, K.S.; Niece, K.L.; Chung, K.K.; Cannon, J.W.; Cota, J.M.; Murray, C.K. Modified augmented renal clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. J. Trauma Acute Care Surg. 2014, 77, 163.
Carlier, M.; Carrette, S.; Roberts, J.A.; Stove, V.; Verstraete, A.; Hoste, E.; Depuydt, P.; Decruyenaere, J.; Lipman, J.; Wallis, S.C.; et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit. Care (Lond. Engl.) 2013, 17, R84.
Binder, L.; Schworer, H.; Hoppe, S.; Streit, F.; Neumann, S.; Beckmann, A.; Wachter, R.; Oellerich, M.; Walson, P.D. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther. Drug Monit. 2013, 35, 63–70.
Goboova, M.; Kuzelova, M.; Fazekas, T.; Kissova, V.; Kakosova, V.; Salkovska, L. The impact of therapeutic drug monitoring (TDM) in optimizing dosage regimens of gentamicin in patients with augmented renal clearance. Int. J. Clin. Pharm. 2016, 38, 596.
Roberts, J.A.; Cotta, M.O.; Cojutti, P.; Lugano, M.; Rocca, G.D.; Pea, F. Does critical illness change levofloxacin pharmacokinetics? Antimicrob. Agents Chemother. 2016, 60, 1459–1463.
Spencer, D.D.; Jacobi, J.; Juenke, J.M.; Fleck, J.D.; Kays, M.B. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy 2011, 31, 934–941.
Patsalos PN, Bery DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannenssen SI, et al. Antiepileptic drugs----best practice guidelines for therapeutic drug monitoring:A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239---71.
Abdel El Naeem, H.E.M.; Abdelhamid, M.H.E.; Atteya, D.A.M. Impact of augmented renal clearance on enoxaparin therapy in critically ill patients. Egypt. J. Anaesth. 2017, 33, 113–117
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Revista Electrónica AnestesiaR
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Envío y derechos de autor